Investigation on the Effect of Different Disintegrants on the Orodispersible Tablets of Rabeprazole

Balamurali, V.; Sreenivas, S. A.; Gangadharappa, H.V.; Pramodkuma, T.M.

doi:10.3923/ajsr.2009.190.197

Cited by 3 publications

(5 citation statements)

References 10 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Tablets containing 10% crospovidone had the fastest dispersion time of 8 s [ 288 ]. These results confirm those obtained by Balamuralidhara et al [ 289 ], who conducted a study comparing 5 disintegrants at concentrations of 5% and 10% used to produce ODTs with rabeprazole. The fastest disintegration time was obtained for the formulation containing 10% crospovidone [ 289 ].…”

Section: Development Of New Formulations With Ppissupporting

confidence: 91%

“…These results confirm those obtained by Balamuralidhara et al [ 289 ], who conducted a study comparing 5 disintegrants at concentrations of 5% and 10% used to produce ODTs with rabeprazole. The fastest disintegration time was obtained for the formulation containing 10% crospovidone [ 289 ]. Moreover, an innovative method for producing ODTs with omeprazole was developed by Alhusban et al [ 286 ].…”

Section: Development Of New Formulations With Ppissupporting

confidence: 91%

See 1 more Smart Citation

Formulation of Dosage Forms with Proton Pump Inhibitors: State of the Art, Challenges and Future Perspectives

2022

View full text Add to dashboard Cite

Since their introduction to pharmacotherapy, proton pump inhibitors (PPIs) have been widely used in the treatment of numerous diseases manifested by excessive secretion of gastric acid. Despite that, there are still unmet needs regarding their availability for patients of all age groups. Their poor stability hinders the development of formulations in which dose can be easily adjusted. The aim of this review is to describe the discovery and development of PPIs, discuss formulation issues, and present the contemporary solutions, possibilities, and challenges in formulation development. The review outlines the physicochemical characteristics of PPIs, connects them with pharmacokinetic and pharmacodynamic properties, and describes the stability of PPIs, including the identification of the most important factors affecting them. Moreover, the possibilities for qualitative and quantitative analysis of PPIs are briefly depicted. This review also characterizes commercial preparations with PPIs available in the US and EU. The major part of the review is focused on the presentation of the state of the art in the development of novel formulations with PPIs covering various approaches employed in this process: nanoparticles, microparticles, minitablets, pellets, bilayer, floating, and mucoadhesive tablets, as well as parenteral, transdermal, and rectal preparations. It also anticipates further possibilities in the development of PPIs dosage forms. It is especially addressed to the researchers developing new formulations containing PPIs, since it covers the most important formulary issues that need to be considered before a decision on the selection of the formula is made. It may help in avoiding unnecessary efforts in this process and choosing the best approach. The review also presents an up-to-date database of publications focused on the pharmaceutical technology of formulations with PPIs.

show abstract

Section: Development Of New Formulations With Ppissupporting

confidence: 91%

Section: Development Of New Formulations With Ppissupporting

confidence: 91%

Formulation of Dosage Forms with Proton Pump Inhibitors: State of the Art, Challenges and Future Perspectives

2022

View full text Add to dashboard Cite

show abstract

“…The comparison of the IR spectrum of pure drug with that of Fc, Fs, and Ft showed all the characteristic peaks of pure Valsartan and revealed that there is no obvious change in the positions of the characteristic absorption bands of groups and bonds. This clearly suggests that the drug remains in the same form even in its formulations indicating that there is no interaction between the drug and excipients were used for the preparation of Valsartan sachet (Balamuralidhara et al, 2009).…”

Section: Drug-excipient Compatibility Study By Ftir Analysismentioning

confidence: 94%

“…IR spectrum of pure Valsartan powder showed characteristic peaks at 2963.09 cm −1 due to C=N stretching, at 1731.76 cm −1 due to carboxylate stretching. The spectra also showed bands at 1731.76 cm −1 due to C=O bending and at 1105.01 cm −1 due to C-N bonding (Balamuralidhara et al, 2009).…”

Section: Drug-excipient Compatibility Studymentioning

confidence: 96%

“…The percentage of drug content uniformity of the prepared Valsartan sachet (Fc, Fs, and Ft) complies with USP criteria. It was found that no sachet from ten sachets lies out of the label claim (Balamuralidhara et al, 2009), which indicates a uniform drug distribution and a proper dose of the drug in the sachet. Therefore, the results indicate that there were a non-significant differences (P > 0.05) between Fc, Fs, and Ft with Fd.…”

Section: Weight Content Uniformitymentioning

confidence: 99%

See 1 more Smart Citation

Impact of Solubility Enhancement Methods on the Dissolution Rate of Valsartan Sachet

2021

View full text Add to dashboard Cite

The oral drug delivery is the most generally used route of administration that has been explored for the delivery of drugs through various pharmaceutical products. Solubility of drug plays critical role in achieving the optimum therapeutic levels of the drug in blood and thus bioavailability. There are many drugs of various therapeutic categories fall in Biopharmaceutics Classification System Classes II and IV as they lack solubility. For all these drugs, dissolution is the big issue for the absorption process. Valsartan is an effective antihypertensive agent and it can be used for the treatment of hypertension in most cases. The objective of this study is to prepare Valsartan as an oral sachet which can be used as an alternative dosage form after improvement of drug solubility using solubilizing agents such as sodium lauryl sulfate and tween 80. Three different formulas of Valsartan sachet were prepared by conventional technique of wet granulation method named conventional formula (Fc), sodium lauryl sulfate formula (Fs), and tween 80 formula (Ft) then compared with the available marketed product of Valsartan tablet (Fd) as a reference. The preformulations studies were conducted to exclude drug excipients interaction. Evaluation was performed in terms of weight variation, dose content uniformity, and drug release study using dissolution test apparatus. Fourier Transforms Infrared Spectroscopy reveals no drug excipient interaction and the drug release profile for Fs and Ft formulas within 30 min was 100.16% and 104.16%, respectively, while for Fc only 57.55% of the drug was released. This difference in the release profile was statistically significant (P < 0.05) between Fs and Ft with Fc, but a non- significant difference (P > 0.05) was observed between Fs and Ft with the marketed Valsartan tablet (Fd). The results support the possibility of using the prepared formulas Fs and Ft as a Valsartan sachet for the oral administration alternative to conventional Valsartan tablets Fd.

show abstract

Development of a New Carvedilol Tablet with Rapid Onset of Action

Makky¹,

Ahmed²,

El-Nabaraw³

et al. 2012

American J. of Drug Discovery and Development

View full text Add to dashboard Cite

Investigation on the Effect of Different Disintegrants on the Orodispersible Tablets of Rabeprazole

Cited by 3 publications

References 10 publications

Formulation of Dosage Forms with Proton Pump Inhibitors: State of the Art, Challenges and Future Perspectives

Formulation of Dosage Forms with Proton Pump Inhibitors: State of the Art, Challenges and Future Perspectives

Impact of Solubility Enhancement Methods on the Dissolution Rate of Valsartan Sachet

Development of a New Carvedilol Tablet with Rapid Onset of Action

Contact Info

Product

Resources

About